New α-MSH Peptides Show Anti-Inflammatory Effects Beyond Core Sequence

The peptide α-melanocyte-stimulating hormone (α-MSH) is a well-established endogenous anti-inflammatory agent, primarily acting through melanocortin receptors (MC1-R, MC3-R, MC4-R, MC5-R). Its anti-inflammatory properties are often attributed to a minimal active sequence, known as the pharmacophore. This study investigated whether α-MSH-related peptides, particularly those outside the classical pharmacophore region, could also exert significant anti-inflammatory effects, aiming to uncover novel mechanisms and therapeutic targets.

The study revealed that several α-MSH-related peptides, particularly those derived from the C-terminal region and previously considered inactive, exhibited potent anti-inflammatory effects. For instance, a specific C-terminal fragment, α-MSH(11-13), significantly reduced TNF-α secretion in LPS-stimulated macrophages by 43% (p<0.01) compared to vehicle-treated controls. Furthermore, another novel analog, [Lys11]-α-MSH(11-13), demonstrated a 2.5-fold decrease in IL-6 production and a 3.1-fold reduction in prostaglandin E2 (PGE2) levels in activated PBMCs, showcasing its broad anti-inflammatory profile. The most important finding was that these anti-inflammatory effects were largely independent of classical melanocortin receptor 1 (MC1R) activation, suggesting novel, non-canonical pathways for α-MSH's immunomodulatory actions, with one peptide reducing NF-κB activation by 55% (p<0.005).